These independent CME/CE activities are supported by educational grants from Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Sanofi Genzyme and Regeneron Pharmaceuticals.



  1. Course List
Selecting the most appropriate biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) for initial or subsequent treatment in patients with rheumatoid arthritis is a challenge for clinicians. Reliable evidence indicating the superiority of any of the DMARDs is rare. However, the evidence to date may be analyzed to point clinicians to the most appropriate choices for a given patient. Join Dr. Marc D. Cohen as he considers the factors and discusses the relevant studies that permit comparison between available DMARDs. Throughout the discussion you will find videos, journal articles, and other sources to enhance understanding of relevant issues.
  • Evaluate comparative efficacy and safety data as well as patient characteristics to select optimal initial and subsequent treatment for patients with rheumatoid arthritis.
  • Target Audience

    This CME/CE program is designed for rheumatologists, primary care providers (internists and family practice practitioners), nurses/nurse practitioners, pharmacists, and physician assistants who treat patients with rheumatoid arthritis and juvenile idiopathic arthritis.

     

    Activity Goal

    The goal of this CME/CE activity is to provide essential information on etiology/pathophysiology, the importance of early diagnosis and treatment, and clinical data on approved and investigational therapies, in order to help improve the management of patients with rheumatoid arthritis.